Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

× No keyword cloud information.

307 in total

1. A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer.

Authors: S Cascinu; R R Silva; R Labianca; S Barni; R Mattioli; G Martignoni; L Frontini; G Gasparini; V Catalano; A M Baldelli; L Giuliodori; R Agostinelli; G Catalano
Journal: Ann Oncol Date: 1999-08 Impact factor: 32.976

2. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study.

Authors: C Cripps; M Burnell; J Jolivet; G Batist; W Lofters; J Dancey; J Iglesias; B Fisher; E A Eisenhauer
Journal: Ann Oncol Date: 1999-10 Impact factor: 32.976

Review 3. Metastatic bladder cancer: advances in treatment.

Authors: W M Stadler; T M Kuzel; D Raghavan; E Levine; N J Vogelzang; B Roth; F A Dorr
Journal: Eur J Cancer Date: 1997-01 Impact factor: 9.162

4. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).

Authors: A Y Chang; K Kim; H Boucher; P Bonomi; J A Stewart; D D Karp; R H Blum
Journal: Cancer Date: 1998-01-15 Impact factor: 6.860

5. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.

Authors: J Aparicio; J M Vicent; I Maestu; S Garcerá; I Busquier; C Bosch; C Llorca; R Díaz; C Fernández-Martos; A Galán
Journal: Ann Oncol Date: 2003-07 Impact factor: 32.976

6. Expression of dihydrofolate reductase and multidrug resistance genes in trimetrexate-resistant human leukemia cell lines.

Authors: X K Li; H Kobayashi; J F Holland; T Ohnuma
Journal: Leuk Res Date: 1993-06 Impact factor: 3.156

7. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma.

Authors: L G Feun; W A Robinson; N Savaraj; R Gonzalez; A Liebmann; K Offenhauser; N J Clendeninn
Journal: Am J Clin Oncol Date: 1995-12 Impact factor: 2.339

8. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).

Authors: P Baas; A Ardizzoni; F Grossi; K Nackaerts; G Numico; E Van Marck; M van de Vijver; F Monetti; M J A Smid-Geirnaerdt; N van Zandwijk; C Debruyne; C Legrand; G Giaccone
Journal: Eur J Cancer Date: 2003-02 Impact factor: 9.162

9. Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products.

Authors: J J McGuire; P Hsieh; J K Coward; J R Bertino
Journal: J Biol Chem Date: 1980-06-25 Impact factor: 5.157

10. Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.

Authors: J Feliu; A Salud; P Escudero; L López-Gómez; C Pericay; C Castañón; M R López de Tejada; J M Rodríguez-García; M P Martínez; M Sanz Martín; J J Sánchez; M González Barón
Journal: Br J Cancer Date: 2004-04-19 Impact factor: 7.640

38 in total

Review 1. Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors: Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal: Clin Pharmacokinet Date: 2016-03 Impact factor: 6.447

2. Antithymidylate resistance enables transgene selection and cell survival for T cells in the presence of 5-fluorouracil and antifolates.

Authors: D Rushworth; A Alpert; R Santana-Carrero; S Olivares; D Spencer; L J N Cooper
Journal: Gene Ther Date: 2015-08-14 Impact factor: 5.250

3. Human constitutive androstane receptor mediated methotrexate induction of human dehydroepiandrosterone sulfotransferase (hSULT2A1).

Authors: Xinrong Chen; Jimei Zhang; Sharon M Baker; Guangping Chen
Journal: Toxicology Date: 2006-12-22 Impact factor: 4.221

4. Substrate channeling between the human dihydrofolate reductase and thymidylate synthase.

Authors: Nuo Wang; J Andrew McCammon
Journal: Protein Sci Date: 2015-06-29 Impact factor: 6.725

Review 5. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors: Young Hee Choi; Ai-Ming Yu
Journal: Curr Pharm Des Date: 2014 Impact factor: 3.116

6. Synthesis and evaluation of a classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates.

Authors: Aleem Gangjee; Jie Yang; John J McGuire; Roy L Kisliuk
Journal: Bioorg Med Chem Date: 2006-09-20 Impact factor: 3.641

Review 7. Reprogramming of serine, glycine and one-carbon metabolism in cancer.

Authors: Albert M Li; Jiangbin Ye
Journal: Biochim Biophys Acta Mol Basis Dis Date: 2020-05-19 Impact factor: 5.187

Review 8. Targeting Metabolism for Cancer Therapy.

Authors: Alba Luengo; Dan Y Gui; Matthew G Vander Heiden
Journal: Cell Chem Biol Date: 2017-09-21 Impact factor: 8.116

9. Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells.

Authors: Anna Tochowicz; Sean Dalziel; Oliv Eidam; Joseph D O'Connell; Sarah Griner; Janet S Finer-Moore; Robert M Stroud
Journal: J Med Chem Date: 2013-06-21 Impact factor: 7.446

10. The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasis.

Authors: Ilan Ifergan; Gerrit Jansen; Yehuda G Assaraf
Journal: J Biol Chem Date: 2008-05-22 Impact factor: 5.157